Micromet's cancer drug portfolio draws big drugmakers' attention

06/14/2010 | Bloomberg Businessweek

Biotech firm Micromet was able to secure a partnership with major drugmakers, including Bayer and Boehringer Ingelheim, because of its line of cancer treatments that might boost the effectiveness of rival medicines. Blinatumomab, Micromet's drug candidate for acute lymphocytic leukemia, led to complete remission during a clinical trial in about 80% of patients who still had leukemia cells after undergoing different forms of chemotherapy.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR